In parallel with these results, in a study using cell lines and CML samples, the combined treatment of imatinib and S63845, a MCL1 inhibitor, was reported to exhibit apoptotic effects on primary human CD34 + CML stem/progenitor cells and sensitive and resistant cell lines. The gene discussed is MCL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.